Ra Pharmaceuticals Inc (RARX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Doug Treco
Employees:
72
87 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA 02140
(617) 401-4060

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It provides pharmaceutical products for treatment of diseases of complement dysregulation. It utilizes small molecules and peptide to address pathological targets in the complement cascade. It develops a portfolio of drugs and partnerships focused on intracellular protein-protein interactions and other innovative approaches for addressing unmet medical needs. The company was founded by Doug A. Treco and James W. Broderick in 2008 and is headquartered in Cambridge, MA.

Data derived from most recent annual or quarterly report
Market Cap 2.274 Billion Shares Outstanding47.389 Million Avg 30-day Volume 1.87 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.79
Price to Revenue740.3814 Debt to Equity0.0 EBITDA-105.383 Million
Price to Book Value8.474 Operating Margin-3565.9667 Enterprise Value1.956 Billion
Current Ratio14.785 EPS Growth-0.121 Quick Ratio14.263
1 Yr BETA 0.3884 52-week High/Low 0.0 / Profit Margin-3422.9333
Operating Cash Flow Growth-58.9943 Altman Z-Score58.8887 Free Cash Flow to Firm -74.711 Million
View SEC Filings from RARX instead.

View recent insider trading info

Ra Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding RARX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding RARX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2020-04-03 by NEW ENTERPRISE ASSOCIATES 13 LP
  • 4: filed on 2020-04-03 by MATHERS EDWARD T
  • 4: filed on 2020-04-03 by TRECO DOUGLAS A
  • 4: filed on 2020-04-03 by LUBNER DAVID CHARLES
  • 4: filed on 2020-04-03 by RICARDO ALONSO
  • 4: filed on 2020-04-03 by READ SIMON
  • 4: filed on 2020-04-03 by FARZANEH-FAR RAMIN
  • 4: filed on 2020-04-03 by Shah Rajeev M.
  • 4: filed on 2020-04-03 by Heft Robert
  • 4: filed on 2020-04-03 by RA CAPITAL MANAGEMENT, L.P.

    • Events (8k)

  • 8-K: filed on 2020-03-31:
    Item 8.01: Other Events
  • 8-K: filed on 2019-12-18:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2019-11-25:
    Item 8.01: Other Events
  • 8-K: filed on 2019-10-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-07-26:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-07-16:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2019-06-12:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2018-12-14:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-12-11:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2018-12-10:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    NEW ENTERPRISE ASSOCIATES 13 LP

    NEA PARTNERS 13, LIMITED PARTNERSHIP

    NEA 13 GP, LTD

    BASKETT FOREST

    KERINS PATRICK J

    SANDELL SCOTT D

    • 10% Owner
    		 No longer subject to file 2020-04-02 0

    RA CAPITAL MANAGEMENT, L.P.

    RA CAPITAL HEALTHCARE FUND LP

    KOLCHINSKY PETER

    • Director
    • 10% Owner
    		 No longer subject to file 2020-04-02 0

    MATHERS EDWARD T

    • Director
    		 No longer subject to file 2020-04-02 0

    PEARSON TIMOTHY R

    • Director
    		 No longer subject to file 2020-04-02 0

    LUBNER DAVID CHARLES EXECUTIVE VP AND CFO

    • Officer
    		 No longer subject to file 2020-04-02 0

    SHAH RAJEEV M.

    • Director
    • 10% Owner
    		 No longer subject to file 2020-04-02 0

    CUMBO ALEXANDER

    • Director
    		 No longer subject to file 2020-04-02 0

    TRECO DOUGLAS A PRESIDENT AND CEO

    • Officer
    • Director
    		 No longer subject to file 2020-04-02 0

    FARZANEH-FAR RAMIN CHIEF MEDICAL OFFICER

    • Officer
    		 No longer subject to file 2020-04-02 0

    READ SIMON CHIEF SCIENTIFIC OFFICER

    • Officer
    		 No longer subject to file 2020-04-02 0

    HEFT ROBERT

    • Director
    		 No longer subject to file 2020-04-02 0

    BRENNAN AOIFE

    • Director
    		 No longer subject to file 2020-04-02 0

    KING JOHN C CHIEF COMMERCIAL OFFICER

    • Officer
    		 No longer subject to file 2020-04-02 0

    RICARDO ALONSO SEE REMARKS

    • Officer
    		 No longer subject to file 2020-04-02 0

    NEW ENTERPRISE ASSOCIATES 13 LP

    NEA PARTNERS 13, LIMITED PARTNERSHIP

    NEA 13 GP, LTD

    BARRIS PETER J

    BASKETT FOREST

    KERINS PATRICK J

    MOTT DAVID M

    SANDELL SCOTT D

    • 10% Owner
    		 6,135,234 2018-12-14 0

    BISGAARD PETER

    • Director
    		 0 2018-06-28 0

    NEW ENTERPRISE ASSOCIATES 13 LP

    NEA PARTNERS 13, LIMITED PARTNERSHIP

    NEA 13 GP, LTD

    BARRETT M JAMES

    BARRIS PETER J

    BASKETT FOREST

    KERINS PATRICK J

    MOTT DAVID M

    SANDELL SCOTT D

    VISWANATHAN RAVI

    • 10% Owner
    		 5,490,073 2018-02-16 0

    RA CAPITAL MANAGEMENT, LLC

    KOLCHINSKY PETER

    • Director
    		 0 2017-06-20 0

    LETTMANN JASON

    • Director
    • 10% Owner
    		 0 2017-06-20 0

    NOVARTIS BIOVENTURES LTD

    NOVARTIS AG

    • 10% Owner
    		 No longer subject to file 2017-06-16 0

    BARRIS PETER J

    • 10% Owner
    		 3,490,073 2016-10-31 0

    BARRETT M JAMES

    • 10% Owner
    		 3,490,073 2016-10-31 0

    MOTT DAVID M

    • 10% Owner
    		 3,490,073 2016-10-31 0

    KERINS PATRICK J

    • 10% Owner
    		 3,490,073 2016-10-31 0

    SANDELL SCOTT D

    • 10% Owner
    		 3,490,073 2016-10-31 0

    KOLLURI KRISHNA KITTU

    • 10% Owner
    		 3,490,073 2016-10-31 0

    BASKETT FOREST

    • 10% Owner
    		 3,490,073 2016-10-31 0

    WELLER HARRY R

    • 10% Owner
    		 3,490,073 2016-10-31 0

    NOVO A/S

    • 10% Owner
    		 No longer subject to file 2016-10-31 0

    MORGENTHALER VENTURE PARTNERS IX LP

    MORGENTHALER MANAGEMENT PARTNERS IX, LLC

    • 10% Owner
    		 2,745,846 2016-10-31 0

    NEW ENTERPRISE ASSOCIATES 13 LP

    NEA PARTNERS 13, LIMITED PARTNERSHIP

    NEA 13 GP, LTD

    • 10% Owner
    		 3,490,073 2016-10-31 0

    VISWANATHAN RAVI

    • 10% Owner
    		 3,490,073 2016-10-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments